Medtronic Dodges Two Of Three Claims In Pain-Pump Suit
An Indiana federal judge axed two components of a patient’s lawsuit against Medtronic, while allowing a manufacturing defect complaint to move forward.
You may also be interested in...
A new cost-effectiveness study shows cancer patients using targeted drug delivery with Medtronic’s SynchroMed II infusion system and conventional medical management incur lower overall health care costs than patients using conventional medical management alone.
Medtronic has agreed to the US FDA’s demands to stop making and distributing the SynchroMed II implantable infusion pumps, except in limited circumstances, until the company corrects quality system violations identified by the agency.
A group of manufacturers and clinicians is asking the US agency to allow more discussion between manufacturers, labs and clinicians of how genetic factors could influence drug effectiveness – an area known as pharmacogenomics (PGx). The FDA had previously taken several steps to limit these communications.